PCCTC investigator @dangeorgemd.bsky.social of Duke University discusses the role of radioligand therapy in prostate cancer management: www.onclive.com/view/dr-geor...

The PCCTC plans on hiring three summer interns to support our Data Management, Data Science, and Clinical Operations teams. The 10-week internships are full-time, paid, 100% remote, and working hours are 9-5 EST. To learn more visit www.pcctc.org/news/2026-su...

Prostate Cancer Clinical Trials Consortium (PCCTC) Innovation Featured at Biocom California’s “Innovations in Oncology Clinical Trial Design” Forum www.linkedin.com/pulse/prosta...

Just published - DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis www.nature.com/articles/s41...

The PCCTC's phase 2 study of talazoparib with or without enzalutamide in patients With metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) is now actively enrolling. To learn more visit clinicaltrials.gov/study/NCT068...

The first site for the first-in-human KTX-2001 STRIKE-001 prostate cancer study has been activated at USA Clinical Trials (San Antonio, TX)—setting a PCCTC benchmark from reg packet distribution to site initiation. www.linkedin.com/posts/k36-th...

We are proud to collaborate with the Latin American Cooperative Oncology Group (LACOG) on innovative multicenter clinical studies like DORA and the IRONMAN Registry www.linkedin.com/embed/feed/u...

PCCTC investigators publish results from the phase 1b DeLLpro-300 study of tarlatamab in patients with neuroendocrine prostate cancer: aacrjournals.org/clincancerre...

Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for mHSPC Intensified by ARPI: A Multinational Real-World Analysis of the IRONMAN Registry. Story via UroToday: www.urotoday.com/conference-h...

PCCTC investigator Rana McKay, MD, outlines key findings from the phase 2 COMRADE trial via Urology Times www.urologytimes.com/view/rana-mc...

Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management @ucsdhealth.bsky.social #ProstateCancer #PCSM www.onclive.com/view/consens...

Such an honor and so much fun to join the Cancer Clear and Simple @uwhealth.bsky.social Carbone Cancer Center Podcast to discuss liquid biopsies in cancer! cancer.wisc.edu/community-ou...

PCCTC investigator Michael A. Carducci, MD discusses consensus recommendations for PARP inhibitor use in metastatic prostate cancer with Alan Bryce, MD via UroToday: www.urotoday.com/video-lectur...

Learn more about the PCCTC-managed PROMISE, a registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes: www.prostatecancerpromise.org

Esteemed PCCTC investigator Dr Rana McKay discusses the exciting developments in biomarker-driven therapy for metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/emergin...

Mark Your Calendar! 🙌🏾🙌🏽🙌🏿 We’re headed to Lagos for the IRONMAN Conference from September 2nd through the 5th. This isn’t just an event, it’s a major milestone in global health and cancer research you won’t want to miss! Register now: surveys.mayoclinic.org/jfe/form/SV_...

PCCTC investigator Dr Rana McKay and colleagues discuss personalizing treatment intensification in metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/persona...

Just published: Analysis from the TRANSFORMER prostate cancer study reveals baseline testosterone could be considered in the treatment selection process when bipolar androgen therapy is an option www.nature.com/articles/s41...

From PCCTC investigator Dr Rana McKay and colleagues, "Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies," published in Eur Urol Oncol www.sciencedirect.com/science/arti...

Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for Metastatic Hormone-Sensitive Prostate Cancer Intensified by Androgen-Receptor Pathway Inhibitors: A Multinational Real-World Analysis of the PCCTC-managed IRONMAN Registry www.urotoday.com/conference-h...

Learn more about TALENT, the PCCTC-managed study of talazoparib with or without enzalutamide in people with #prostatecancer who have previously received abiraterone (NCT06844383): www.pcctc.org/talent

#ASCO25: PCCTC investigator Dr Rana McKay discusses the COMRADE study, "The combination of olaparib with radium-223 demonstrated feasibility, safety, and antitumor activity in patients with metastatic castration-resistant #prostatecancer with bone metastases”

PCCTC study of a novel CTLA-engaging IO plus Lu177-PSA-617 therapy in patients with metastatic castration-resistant #prostatecancer (mCRPC) at #ASCO25 #MedIQASCO25 with @tiansterzhangmd.bsky.social. Clear activity and safe!

Join us tomorrow (Tuesday) at #ASCO25 as PCCTC investigators present at the prostate cancer oral abstract session (Hall D1 and Live Stream)!

#ASCO25: PCCTC investigators Drs Karen Autio, Michael Schweizer, and Mark Stein contribute to first-in-human results for novel T-cell engager pasritamig (JNJ-78278343), showing early anti-tumor activity in #prostatecancer www.jnj.com/media-center...

The PCCTC at #ASCO25 via UroToday: A Randomized, Open-Label, Phase 2b Study of the Bromodomain Inhibitor ZEN-3694 + Enzalutamide vs Enzalutamide in Patients with mCRPC www.urotoday.com/conference-h...

Today at #ASCO25, Rapid Oral Sessions featuring PCCTC #prostatecancer science: the phase 2 Metacure trial, the novel B7H3 ADC DB‑1311/BNT324, and the phase 1 study results of JNJ-78278343

Mark Your Calendar! 📆 We’re headed to Lagos for the IRONMAN Conference from September 2nd through the 5th. This isn’t just an event, it’s a major milestone in global health and cancer research you won’t want to miss! Register now: surveys.mayoclinic.org/jfe/form/SV_...

DOD prostate cancer research program FY25 funding opportunities https://cancerletter.com/funding-opportunities/20250523_10a/

#ASCO25 is just days away. Be sure to check out the innovative PCCTC prostate cancer clinical research presented at this year's annual meeting in Chicago!

We are excited to announce science from innovative PCCTC multi-center prostate cancer studies will be represented by 16 abstracts at #ASCO25!

At MSK, there are exciting new therapies that are proving effective at treating metastatic prostate cancer. In this 📹, Dr. Michael Morris, a genitourinary medical oncologist and the Prostate Cancer Section Head at MSK, speaks about one in particular. Plus, read more here: bit.ly/4mfOKhg

The PCCTC's Dr. Michael J. Morris and other experts weigh in on President Biden's prostate cancer diagnosis and the debate about prostate screenings for older men: www.washingtonpost.com/health/2025/...

We’re headed to Lagos for the IRONMAN Conference from September 4–6, with a special pre-conference session on September 3. This isn’t just an event—it’s a major milestone in global health and cancer research you won’t want to miss! Register now: surveys.mayoclinic.org/jfe/form/SV_...

Just published: PCCTC study of Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer by Dr Karen A Autio and colleagues: pmc.ncbi.nlm.nih.gov/articles/PMC...

Just Published: PCCTC leadership and colleagues release recommended clinical context and patient context data elements for liquid biopsy data submitted to data repositories and data commons (Clin Transl Sci): pmc.ncbi.nlm.nih.gov/articles/PMC...

🌍 Save the Date! We’re heading to Lagos for the IRONMAN Conference happening September 4–6, with a special pre-conference on September 3. This is more than an event, it’s a milestone you won’t want to miss! Register today: surveys.mayoclinic.org/jfe/form/SV_...

Genitourinary medical oncologist Howard Scher, MD, is serving as chairperson for a session on diagnostic and predictive biomarkers for cancer. @mskcancercenter.bsky.social @theaacr.bsky.social Learn more: bit.ly/3Gwdvpe

Congratulations, Howard I. Scher, MD, recipient of the Urology Care Foundation's Richard D. Williams, MD Prostate Cancer Research Excellence Award!

#AACR25: Two proffered abstracts detailing the PCCTC-managed International Registry for Men With Advanced Prostate Cancer (IRONMAN) are featured at this year's AACR Annual Meeting www.aacr.org/meeting/aacr...

Cancer Centers Survivorship Research Forum 2025: Join our colleagues at Dana-Farber Cancer Center for two impactful days of connection, collaboration, and cutting-edge insights in survivorship research! www.eventbrite.com/e/cancer-cen...

PCCTC investigator Dr. Evan Y. Yu discusses the clinical evolution of radiopharmaceuticals for patients with prostate cancer via OncLive

🌍✨ Mark your calendars for the event of the year! Join us in Lagos from September 4th-6th, with a pre-conference on September 3rd, for the IRONMAN Conference and CaPTC’s 20th Anniversary Celebration! You won’t want to miss it! 🔗 Register now: surveys.mayoclinic.org/jfe/form/SV_...

Relationship Between Undetectable PSA Nadir and Outcomes for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in the PCCTC-managed International Registry for Men with Advanced Prostate Cancer (IRONMAN), via UroToday: www.urotoday.com/conference-h...

PCCTC Scientific Oversight Committee Chair @mjmorrismd.bsky.social discusses radioligand therapy strategies for polymetastatic castration-sensitive prostate cancer at the 2025 UCSF-UCLA PSMA Conference: www.urotoday.com/video-lectur...

PCCTC investigators publish encouraging results from their phase 1 study of FOR46, a fully human antibody conjugated to monomethyl auristatin E, in metastatic castration-resistant prostate cancer: ascopubs.org/doi/pdfdirec...

PCCTC investigators and colleagues identify factors associated with successful genetic testing of bone tissue for patients with metastatic prostate cancer (Eur Urol Oncol. 2025 Apr;8(2):355-363): www.sciencedirect.com/science/arti...

PCCTC investigator Dr Rana McKay discusses her systematic review of radium-223 use over the past decade with Dr Alicia Morgans and UroToday: www.urotoday.com/video-lectur...

Budget cuts and research delays threaten to reverse progress on what had been a bipartisan cause

🌍✨ Mark your calendars for the event of the year! Join us in Lagos from September 4th-6th, with a pre-conference on September 3rd, for the IRONMAN Conference and CaPTC’s 20th Anniversary Celebration! You won’t want to miss it! 🔗 Register now: surveys.mayoclinic.org/jfe/form/SV_...